KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EBIT: 2013-2024

Historic EBIT for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$4.4 million.

  • Palvella Therapeutics' EBIT fell 132.62% to -$4.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$14.1 million, marking a year-over-year decrease of 18.75%. This contributed to the annual value of -$14.1 million for FY2024, which is 18.75% down from last year.
  • Palvella Therapeutics' EBIT amounted to -$4.4 million in Q4 2024, which was up 13.75% from -$5.1 million recorded in Q3 2024.
  • In the past 5 years, Palvella Therapeutics' EBIT ranged from a high of $13.4 million in Q4 2023 and a low of -$19.0 million during Q3 2021.
  • Over the past 3 years, Palvella Therapeutics' median EBIT value was -$6.3 million (recorded in 2022), while the average stood at -$5.8 million.
  • Per our database at Business Quant, Palvella Therapeutics' EBIT tumbled by 833.16% in 2020 and then soared by 216.21% in 2023.
  • Palvella Therapeutics' EBIT (Quarterly) stood at -$12.4 million in 2020, then climbed by 11.38% to -$11.0 million in 2021, then fell by 4.73% to -$11.5 million in 2022, then soared by 216.21% to $13.4 million in 2023, then crashed by 132.62% to -$4.4 million in 2024.
  • Its EBIT was -$4.4 million in Q4 2024, compared to -$5.1 million in Q3 2024 and -$2.9 million in Q2 2024.